Dexcom SEC filings, summarized
We read every Dexcom 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track DXCM in your inbox
Add Dexcom to your watchlist — free, every morning.
Recent filings
Dexcom Executive Chair Kevin Sayer sells $2.0M in stock
Kevin Sayer, Dexcom’s executive chair and a director, sold 26,756 shares of common stock on July 20 at $76.32 per share, for approximately $2.04 million. He…
DexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc.
DexCom files 8-K (Item 9.01): Exhibit 10.1 — Letter Agreement dated Feb 27, 2026 between DexCom, Inc. and Kevin Sayer; noted as a management/compensatory…
Kevin R.
Kevin R. Sayer returned from a temporary leave and resumed his role as Executive Chairman of DexCom effective Mar 2, 2026 (he retired as CEO on Jan 1,…
Dexcom filed Form 8‑K on Feb 26, 2026: Item 9.01 lists Exhibit 99.1 (press release dated Feb 26, 2026) and…
Dexcom filed Form 8‑K on Feb 26, 2026: Item 9.01 lists Exhibit 99.1 (press release dated Feb 26, 2026) and Exhibit 104 (Inline XBRL cover page). Report…
Dexcom ($DXCM) announced on Feb 26, 2026 the appointment of Mr.
Dexcom ($DXCM) announced on Feb 26, 2026 the appointment of Mr. Osterloh to its Board. Press release furnished as Exhibit 99.1 to the 8‑K and incorporated…
Dexcom Board expands to 12; appointed Albert F.
Dexcom Board expands to 12; appointed Albert F. “Rick” Osterloh IV as director effective Feb 26, 2026. Term expires at the 2026 annual meeting. He joins the…
Dexcom filed an 8‑K (Item 9.01) on Feb 12, 2026 — exhibits: Press Release (Ex.
Dexcom filed an 8‑K (Item 9.01) on Feb 12, 2026 — exhibits: Press Release (Ex. 99.1) and Inline XBRL Cover Page (Ex. 104). Filing signed by EVP & CFO Jereme…
Dexcom ($DXCM) issued a press release on Feb 12, 2026 announcing financial results for Q4 and FY ended Dec…
Dexcom ($DXCM) issued a press release on Feb 12, 2026 announcing financial results for Q4 and FY ended Dec 31, 2025; release furnished as Exhibit 99.1 —…
DEXCOM filed an 8‑K on Jan 12, 2026 furnishing exhibits: press releases dated Jan 12, 2026 (Ex.99.1) and…
DEXCOM filed an 8‑K on Jan 12, 2026 furnishing exhibits: press releases dated Jan 12, 2026 (Ex.99.1) and Jan 7, 2026 (Ex.99.2), plus Cover Page Inline XBRL…
Dexcom CEO Jake Leach to present at J.P.
Dexcom CEO Jake Leach to present at J.P. Morgan Healthcare Conf on Jan 12, 2026 at 10:30 AM ET — will report preliminary, unaudited Q4 2025 & FY2025 results…
DexCom filed an 8‑K adding an Offer Letter effective Jan 1, 2026 with Jacob S.
DexCom filed an 8‑K adding an Offer Letter effective Jan 1, 2026 with Jacob S. Leach (Ex.10.1 — management/compensatory arrangement). Filing does not…
Dexcom appoints Jacob S.
Dexcom appoints Jacob S. Leach as President & CEO and director effective Jan 1, 2026; he’s been interim CEO during Kevin Sayer’s medical leave. Board…